Over the past year, the pharmaceutical industry’s spotlight has been almost entirely occupied by two events: first, $Eli Lilly(LLY)$ swept the market with its GLP-1 drugs Mounjaro and Zepbound, sending its stock price soaring; second, the little-known Chinese pharmaceutical company Regencell Bioscience (RGC) achieved an astonishing gain of over 21,000%, becoming a carnival for speculators.
Yet while the market obsesses over stars and myths, true value investors often seek opportunities in the overlooked corners. Today, a “struggling” pharmaceutical giant is waiting in the wings— $Pfizer(PFE)$ . Not only does it have a backup plan in the GLP-1 race, but it also offers an attractive 6.4% dividend yield. As Eli Lilly’s price-to-earnings (P/E) ratio is hyped up to 45x and Regencell’s fundamentals are nearly non-existent, Pfizer, with a P/E ratio of just 8.7x, may be the more rational choice.
Eli Lilly’s “Perfect Pricing”: Hidden Risks Behind High Growth
Eli Lilly has indeed delivered an impressive performance: in 2025, Mounjaro sales grew 99%, and Zepbound soared 175%. These two drugs already account for 56% of the company’s total revenue, becoming the absolute growth engine.
But the problem lies precisely here—over-reliance. Eli Lilly is quickly becoming a “one-legged giant.” In the pharmaceutical industry, no drug can escape the patent cliff forever. As more competitors flood the GLP-1 track and generic drugs converge in the future, can the current 45x P/E ratio be sustained? Wall Street’s pricing of Eli Lilly clearly assumes a “perfect ending”: sustained leadership and eternal dominance. Any sign of weakness in performance will bring huge downside risks from this “perfect pricing.” The 0.6% dividend yield also provides investors with almost no safety net.
Regencell’s “Myth”: A Highly Speculative Frenzy That Can’t Be Replicated
Turning to Regencell Bioscience, its over 21,000% gain is indeed staggering, but it is more of a warning sign than a guiding light. A closer look at the Chinese pharmaceutical company’s fundamentals reveals little logic to support such a surge. Lack of blockbuster products, unclear pipeline prospects, and negligible revenue—this is almost a perfect portrayal of “speculation.” For investors pursuing stability, chasing Regencell is equivalent to licking blood from a knife’s edge. Its skyrocketing price may make a few people rich overnight, but more may become the last ones holding the bag in this game of musical chairs.
Pfizer’s “Struggle” and “Counterattack”: A Classic Value Investing Script
Compared to the two above, Pfizer is in a scenario familiar to value investors: short-term pressure, unchanged long-term logic, and extremely attractive valuation. It is undeniable that Pfizer is going through growing pains. In the post-pandemic era, the company’s COVID-19 product line has shrunk significantly; in the next few years, several blockbuster products, including the anticoagulant Eliquis, will face patent expiration. These bad news have been fully digested by the market, even overreacted to, leading to a long-term slump in its stock price.
But the real reversal signals are often hidden in the details:
GLP-1 “Plan B”:
Although internal R&D suffered setbacks, Pfizer quickly adjusted its strategy. It is acquiring biotech companies with promising pipelines while reaching distribution partnerships with enterprises developing oral GLP-1 drugs. More importantly, the candidate drug MET-097i performed excellently in Phase II clinical trials: it not only has strong efficacy but also has potential advantages of fewer side effects and once-monthly dosing. If this drug can be successfully launched, Pfizer still has a chance to stage a comeback in the weight-loss drug market.
Pipeline Depth and Cost Control:
Pfizer’s R&D heritage remains strong. In 2025, the company launched 11 key studies and plans to launch another 20 in 2026. At the same time, through initiatives such as introducing artificial intelligence (AI), Pfizer is significantly cutting costs and improving profit margins. Once new products are approved for launch, profit flexibility will be quickly released.
Irrational Valuation and Generous Dividends:
This is Pfizer’s most direct appeal currently. The forward P/E ratio of 8.7x is far lower than the pharmaceutical industry average of 18.7x. At the same time, the company has clearly stated that it will maintain its dividend during difficult times. The current 6.4% forward dividend yield is itself a considerable safety net for long-term investors. The 51.3% dividend growth record over the past decade also proves the management’s willingness to reward shareholders.
Conclusion: Who Is the Real Value Choice?
Eli Lilly is the current king, but it is already perfectly priced; Regencell is a speculator’s dream, but the wake-up call is often extremely cruel; Pfizer, on the other hand, is a “struggling giant” going through a cyclical trough, yet still possessing a deep moat and high cash returns. For investors pursuing long-term stable returns, rather than chasing the hype at high levels, it is better to deploy at low levels. When market sentiment returns to rationality and Pfizer’s GLP-1 pipeline or other blockbuster new drugs make progress, this forgotten pharmaceutical giant is expected to regain Wall Street’s favor. And while waiting for the reversal, there is at least a 6.4% dividend to accompany you through the cold winter.
For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.
🎉Cash Boost Account Now Supports 35,000+ Stocks & ETFs – Greater Flexibility Now
Find out more here.
Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.
Other helpful links:
-
💰Join the TB Contra Telegram Group to Get $10 Trading Vouchers Now🎉
-
How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.
Comments